About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Cardiac Biomarkers Market Size to grow at a CAGR of 14.2% by 2031
Cardiac Biomarkers Market

Cardiac Biomarkers Market Size, Share & Trends Analysis Report By Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) Or NT-ProBNP, Ischemia Modified Albumin (IMA), ALT/AST, Others), By Location of Testing (Point-of-Care Testing, Laboratory Testing), By Applications (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRPH3448DR
Author : Straits Research
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Cardiac Biomarkers Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Myocardial Muscle Creatine Kinase (CK-MB)
        1. By Value
      3. Troponins (T and I)
        1. By Value
      4. Myoglobin
        1. By Value
      5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
        1. By Value
      6. Ischemia Modified Albumin (IMA)
        1. By Value
      7. ALT/AST
        1. By Value
      8. Others
        1. By Value
    3. By Location of Testing
      1. Introduction
        1. Location of Testing By Value
      2. Point-of-Care Testing
        1. By Value
      3. Laboratory Testing
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Myocardial Infarction
        1. By Value
      3. Congestive Heart Failure
        1. By Value
      4. Acute Coronary Syndrome
        1. By Value
      5. Atherosclerosis
        1. By Value
      6. Others
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Myocardial Muscle Creatine Kinase (CK-MB)
        1. By Value
      3. Troponins (T and I)
        1. By Value
      4. Myoglobin
        1. By Value
      5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
        1. By Value
      6. Ischemia Modified Albumin (IMA)
        1. By Value
      7. ALT/AST
        1. By Value
      8. Others
        1. By Value
    3. By Location of Testing
      1. Introduction
        1. Location of Testing By Value
      2. Point-of-Care Testing
        1. By Value
      3. Laboratory Testing
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Myocardial Infarction
        1. By Value
      3. Congestive Heart Failure
        1. By Value
      4. Acute Coronary Syndrome
        1. By Value
      5. Atherosclerosis
        1. By Value
      6. Others
        1. By Value
    5. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Myocardial Muscle Creatine Kinase (CK-MB)
          1. By Value
        3. Troponins (T and I)
          1. By Value
        4. Myoglobin
          1. By Value
        5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
          1. By Value
        6. Ischemia Modified Albumin (IMA)
          1. By Value
        7. ALT/AST
          1. By Value
        8. Others
          1. By Value
      2. By Location of Testing
        1. Introduction
          1. Location of Testing By Value
        2. Point-of-Care Testing
          1. By Value
        3. Laboratory Testing
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Myocardial Infarction
          1. By Value
        3. Congestive Heart Failure
          1. By Value
        4. Acute Coronary Syndrome
          1. By Value
        5. Atherosclerosis
          1. By Value
        6. Others
          1. By Value
    6. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Myocardial Muscle Creatine Kinase (CK-MB)
        1. By Value
      3. Troponins (T and I)
        1. By Value
      4. Myoglobin
        1. By Value
      5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
        1. By Value
      6. Ischemia Modified Albumin (IMA)
        1. By Value
      7. ALT/AST
        1. By Value
      8. Others
        1. By Value
    3. By Location of Testing
      1. Introduction
        1. Location of Testing By Value
      2. Point-of-Care Testing
        1. By Value
      3. Laboratory Testing
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Myocardial Infarction
        1. By Value
      3. Congestive Heart Failure
        1. By Value
      4. Acute Coronary Syndrome
        1. By Value
      5. Atherosclerosis
        1. By Value
      6. Others
        1. By Value
    5. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Myocardial Muscle Creatine Kinase (CK-MB)
          1. By Value
        3. Troponins (T and I)
          1. By Value
        4. Myoglobin
          1. By Value
        5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
          1. By Value
        6. Ischemia Modified Albumin (IMA)
          1. By Value
        7. ALT/AST
          1. By Value
        8. Others
          1. By Value
      2. By Location of Testing
        1. Introduction
          1. Location of Testing By Value
        2. Point-of-Care Testing
          1. By Value
        3. Laboratory Testing
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Myocardial Infarction
          1. By Value
        3. Congestive Heart Failure
          1. By Value
        4. Acute Coronary Syndrome
          1. By Value
        5. Atherosclerosis
          1. By Value
        6. Others
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Myocardial Muscle Creatine Kinase (CK-MB)
        1. By Value
      3. Troponins (T and I)
        1. By Value
      4. Myoglobin
        1. By Value
      5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
        1. By Value
      6. Ischemia Modified Albumin (IMA)
        1. By Value
      7. ALT/AST
        1. By Value
      8. Others
        1. By Value
    3. By Location of Testing
      1. Introduction
        1. Location of Testing By Value
      2. Point-of-Care Testing
        1. By Value
      3. Laboratory Testing
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Myocardial Infarction
        1. By Value
      3. Congestive Heart Failure
        1. By Value
      4. Acute Coronary Syndrome
        1. By Value
      5. Atherosclerosis
        1. By Value
      6. Others
        1. By Value
    5. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Myocardial Muscle Creatine Kinase (CK-MB)
          1. By Value
        3. Troponins (T and I)
          1. By Value
        4. Myoglobin
          1. By Value
        5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
          1. By Value
        6. Ischemia Modified Albumin (IMA)
          1. By Value
        7. ALT/AST
          1. By Value
        8. Others
          1. By Value
      2. By Location of Testing
        1. Introduction
          1. Location of Testing By Value
        2. Point-of-Care Testing
          1. By Value
        3. Laboratory Testing
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Myocardial Infarction
          1. By Value
        3. Congestive Heart Failure
          1. By Value
        4. Acute Coronary Syndrome
          1. By Value
        5. Atherosclerosis
          1. By Value
        6. Others
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Myocardial Muscle Creatine Kinase (CK-MB)
        1. By Value
      3. Troponins (T and I)
        1. By Value
      4. Myoglobin
        1. By Value
      5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
        1. By Value
      6. Ischemia Modified Albumin (IMA)
        1. By Value
      7. ALT/AST
        1. By Value
      8. Others
        1. By Value
    3. By Location of Testing
      1. Introduction
        1. Location of Testing By Value
      2. Point-of-Care Testing
        1. By Value
      3. Laboratory Testing
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Myocardial Infarction
        1. By Value
      3. Congestive Heart Failure
        1. By Value
      4. Acute Coronary Syndrome
        1. By Value
      5. Atherosclerosis
        1. By Value
      6. Others
        1. By Value
    5. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Myocardial Muscle Creatine Kinase (CK-MB)
          1. By Value
        3. Troponins (T and I)
          1. By Value
        4. Myoglobin
          1. By Value
        5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
          1. By Value
        6. Ischemia Modified Albumin (IMA)
          1. By Value
        7. ALT/AST
          1. By Value
        8. Others
          1. By Value
      2. By Location of Testing
        1. Introduction
          1. Location of Testing By Value
        2. Point-of-Care Testing
          1. By Value
        3. Laboratory Testing
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Myocardial Infarction
          1. By Value
        3. Congestive Heart Failure
          1. By Value
        4. Acute Coronary Syndrome
          1. By Value
        5. Atherosclerosis
          1. By Value
        6. Others
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Myocardial Muscle Creatine Kinase (CK-MB)
        1. By Value
      3. Troponins (T and I)
        1. By Value
      4. Myoglobin
        1. By Value
      5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
        1. By Value
      6. Ischemia Modified Albumin (IMA)
        1. By Value
      7. ALT/AST
        1. By Value
      8. Others
        1. By Value
    3. By Location of Testing
      1. Introduction
        1. Location of Testing By Value
      2. Point-of-Care Testing
        1. By Value
      3. Laboratory Testing
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Myocardial Infarction
        1. By Value
      3. Congestive Heart Failure
        1. By Value
      4. Acute Coronary Syndrome
        1. By Value
      5. Atherosclerosis
        1. By Value
      6. Others
        1. By Value
    5. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Myocardial Muscle Creatine Kinase (CK-MB)
          1. By Value
        3. Troponins (T and I)
          1. By Value
        4. Myoglobin
          1. By Value
        5. Brain Natriuretic Peptide (BNPs) Or NT-ProBNP
          1. By Value
        6. Ischemia Modified Albumin (IMA)
          1. By Value
        7. ALT/AST
          1. By Value
        8. Others
          1. By Value
      2. By Location of Testing
        1. Introduction
          1. Location of Testing By Value
        2. Point-of-Care Testing
          1. By Value
        3. Laboratory Testing
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Myocardial Infarction
          1. By Value
        3. Congestive Heart Failure
          1. By Value
        4. Acute Coronary Syndrome
          1. By Value
        5. Atherosclerosis
          1. By Value
        6. Others
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Cardiac Biomarkers Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Abbott
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Quidel Corporation
    3. Siemens
    4. Hoffmann-La Roche Ltd.
    5. Danaher Corporation
    6. Biomérieux SA
    7. Bio-Rad Laboratories Inc.
    8. Randox Laboratories Ltd
    9. Thermo Fisher Scientific Inc.
    10. Johnson & Johnson Services Inc.
    11. Trivitron Healthcare
    12. ACS Biomarker B.V.
    13. Novartis AG
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Biomarkers Market Size The global biomarkers market size was valued at USD 89.81 billion in 2024 and is projected to reach from USD 101.37 billion in 2025 to USD 267.22 billion by 2033, growing at a CAGR of 12.88% 
Buy Now
Global Report
The global cancer biomarker market size was valued at USD 15.86 billion in 2023. It is estimated to reach USD 55.57 billion by 2032, growing at a CAGR of 14.95% during the forecast period (2024–2032). The global cancer biomarker market is prima
Buy Now
Global Report
Digital Biomarkers Market Size The global digital biomarkers market size was valued at USD 3.43 billion in 2023 and is projected to reach USD 49.17 billion by 2032, growing at a CAGR of 34.43% during the forecast period (2024–2032). In recent years,
Buy Now
Global Report
The global renal biomarkers market size was valued at USD 1,119.82 million in 2022. It is estimated to reach USD 2,158.11 million by 2031, growing at a CAGR of 7.56% during the forecast period (2023–2031). Biomarkers are substances that c
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.